Macrogenics Inc (NASDAQ: MGNX) kicked off on Tuesday, down -5.51% from the previous trading day, before settling in for the closing price of $2.54. Over the past 52 weeks, MGNX has traded in a range of $2.53-$21.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 18.02% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -697.81%. With a float of $57.88 million, this company’s outstanding shares have now reached $62.76 million.
In an organization with 339 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 91.14%, operating margin of -75.78%, and the pretax margin is -69.07%.
Macrogenics Inc (MGNX) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Macrogenics Inc is 7.78%, while institutional ownership is 84.15%. The most recent insider transaction that took place on Apr 04 ’24, was worth 799,148. In this transaction Senior VP and General Counsel of this company sold 51,395 shares at a rate of $15.55, taking the stock ownership to the 0 shares. Before that another transaction happened on Mar 06 ’24, when Company’s Senior VP and General Counsel sold 19,625 for $21.50, making the entire transaction worth $421,938. This insider now owns 8,895 shares in total.
Macrogenics Inc (MGNX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.79 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -697.81% per share during the next fiscal year.
Macrogenics Inc (NASDAQ: MGNX) Trading Performance Indicators
Take a look at Macrogenics Inc’s (MGNX) current performance indicators. Last quarter, stock had a quick ratio of 3.69. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.57, a number that is poised to hit -0.37 in the next quarter and is forecasted to reach -2.20 in one year’s time.
Technical Analysis of Macrogenics Inc (MGNX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.0 million. That was better than the volume of 0.69 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 2.14%. Additionally, its Average True Range was 0.18.
During the past 100 days, Macrogenics Inc’s (MGNX) raw stochastic average was set at 1.10%, which indicates a significant decrease from 3.02% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 57.18% in the past 14 days, which was lower than the 62.04% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.19, while its 200-day Moving Average is $4.40. However, in the short run, Macrogenics Inc’s stock first resistance to watch stands at $2.50. Second resistance stands at $2.59. The third major resistance level sits at $2.66. If the price goes on to break the first support level at $2.34, it is likely to go to the next support level at $2.27. The third support level lies at $2.18 if the price breaches the second support level.
Macrogenics Inc (NASDAQ: MGNX) Key Stats
The company with the Market Capitalisation of 150.63 million has total of 62,763K Shares Outstanding. Its annual sales at the moment are 58,750 K in contrast with the sum of -9,060 K annual income. Company’s last quarter sales were recorded 110,710 K and last quarter income was 56,310 K.
